肝动脉灌注化疗和卡瑞利珠单抗联合阿帕替尼（TRIPLET 方案）有望治疗晚期肝细胞癌（Ad-HCC）。然而，TRIPLET 后微波消融 (MWA) 的有用性仍存在争议。为了比较单独 TRIPLET (T-A) 与 TRIPLET-MWA (T-M) 对于 Ad-HCC 的疗效和安全性。从 2018 年 1 月至 2022 年 3 月，217 Ad-回顾性纳入 HCC 患者。其中，T-A组122例，T-M组95例。应用倾向评分匹配（PSM）来平衡偏差。使用 Kaplan-Meier 曲线与对数秩检验比较总生存期 (OS)。还评估了总体客观缓解率（ORR）和主要并发症。PSM后，82例患者被纳入T-A组和T-M组。 T-M组的ORR（85.4%）显着高于T-A组（65.9%）（P < 0.001）。 T-M 组的累积 1 年、2 年和 3 年 OS 率分别为 98.7%、93.4% 和 82.0%，T-A 组分别为 85.1%、63.1% 和 55.0%（风险比 = 0.22；95%）置信区间：0.10-0.49；P < 0.001）。 T-A组主要并发症发生率为4.9%（6/122），T-M组为5.3%（5/95），无显着差异（P = 1.000）。T-M可以提供更好的生存结果和可比较的安全性Ad-HCC 优于 T-A。©作者 2024。百世登出版集团有限公司出版。保留所有权利。

Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.To compare the efficacy and safety of TRIPLET alone (T-A) vs TRIPLET-MWA (T-M) for Ad-HCC.From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (P < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; P < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (P = 1.000).T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.